Do you want to read an article? Please log in or register.
Long-term immune-related adverse events after discontinuation of immunotherapy
Immunotherapy
Related content
COMMENTED
Immunotherapy
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
★ 3
Recommended and commented by
Prof. Dr Dr Sacha Rothschild, Faculty Member
Eur J Cancer
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O
doi: 10.1016/j.ejca.2021.03.010
ImmunotherapyT Cells
Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells
J Autoimmun.
Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P
doi: 10.1016/j.jaut.2019.102310.
Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Ann Rheum Dis.
Kostine M, Finckh A, Bingham CO 3rd, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T
doi: 10.1136/annrheumdis-2020-217139.
Melanoma and Skin Cancer
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma
JAMA Dermatol.
Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T
doi: 10.1001/jamadermatol.
Systemic Sclerosis
Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study
Ann Rheum Dis.
van Bijnen S, de Vries-Bouwstra J, van den Ende CH, Boonstra M, Kroft L, Geurts B, Snoeren M, Schouffoer A, Spierings J, van Laar JM, Huizinga TW, Voskuyl A, Marijt E, van der Velden W, van den Hoogen FH, Vonk MC
doi: 10.1136/annrheumdis-2020-217058.
Further Publications Rheumatology
Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer
Arthritis Rheumatol
Cunningham-Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane LA, Shadick NA, Awad MM, Rahma O, LeBoeuf NR, Gravallese EM, Sparks JA
doi: 10.1002/art.41949
Melanoma and Skin Cancer
C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting
Melanoma Res
Lauwyck J, Beckwée A, Santens A, Schwarze JK, Awada G, Vandersleyen V, Aspeslagh S, Neyns B
doi: 10.1097/CMR.0000000000000748
T CellsImmune Response
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
J Clin Oncol
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M
doi: 10.1200/JCO.21.01992
T Cells
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis
Semin Cancer Biol.
Kumar P, Saini S, Prabhakar BS
doi: 10.1016/j.semcancer.